Advertisement
UK markets closed
  • FTSE 100

    8,247.79
    -33.76 (-0.41%)
     
  • FTSE 250

    20,363.43
    -199.14 (-0.97%)
     
  • AIM

    768.03
    -3.83 (-0.50%)
     
  • GBP/EUR

    1.1843
    +0.0028 (+0.23%)
     
  • GBP/USD

    1.2679
    -0.0009 (-0.07%)
     
  • Bitcoin GBP

    48,713.41
    +809.16 (+1.69%)
     
  • CMC Crypto 200

    1,284.68
    +35.56 (+2.85%)
     
  • S&P 500

    5,461.50
    +13.63 (+0.25%)
     
  • DOW

    39,099.77
    -311.44 (-0.79%)
     
  • CRUDE OIL

    81.20
    -0.43 (-0.53%)
     
  • GOLD FUTURES

    2,337.10
    -7.30 (-0.31%)
     
  • NIKKEI 225

    39,173.15
    +368.50 (+0.95%)
     
  • HANG SENG

    18,072.90
    +45.19 (+0.25%)
     
  • DAX

    18,177.62
    -147.96 (-0.81%)
     
  • CAC 40

    7,662.30
    -44.59 (-0.58%)
     

HUTCHMED Confirms No Assets Held at Silicon Valley Bank

HUTCHMED (China) Limited
HUTCHMED (China) Limited

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today confirms that it does not have any exposure to Silicon Valley Bank (“SVB”) or Silicon Valley Bank UK Limited (“SVBUK”). The Company does not hold any cash deposits or securities with SVB or SVBUK.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/​immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

ADVERTISEMENT

CONTACTS

Investor Enquiries

 

Mark Lee, Senior Vice President

+852 2121 8200

Annie Cheng, Vice President

+1 (973) 306-4490

 

 

Media Enquiries

 

Americas – Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile) / bmiles@soleburystrat.com

Europe – Ben Atwell / Alex Shaw, FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com

Asia – Zhou Yi, Brunswick

+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

 

 

Nominated Advisor

 

Atholl Tweedie / Freddy Crossley, Panmure Gordon

+44 (20) 7886 2500